Unknown

Dataset Information

0

Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats.


ABSTRACT: BACKGROUND:Cyclosporin A (CsA) is a promising therapeutic drug for myocardial ischemia reperfusion injury (MI/RI) because of its definite inhibition to the opening of mitochondrial permeability transition pore (mPTP). However, the application of cyclosporin A to treat MI/RI is limited due to its immunosuppressive effect to other normal organ and tissues. SS31 represents a novel mitochondria-targeted peptide which can guide drug to accumulate into mitochondria. In this paper, mitochondria-targeted nanoparticles (CsA@PLGA-PEG-SS31) were prepared to precisely deliver cyclosporin A into mitochondria of ischemic cardiomyocytes to treat MI/RI. RESULTS:CsA@PLGA-PEG-SS31 was prepared by nanoprecipitation. CsA@PLGA-PEG-SS31 showed small particle size (~?50 nm) and positive charge due to the modification of SS31 on the surface of nanoparticles. CsA@PLGA-PEG-SS31 was stable for more than 30 days and displayed a biphasic drug release pattern. The in vitro results showed that the intracellular uptake of CsA@PLGA-PEG-SS31 was significantly enhanced in hypoxia reoxygenation (H/R) injured H9c2 cells. CsA@PLGA-PEG-SS31 delivered CsA into mitochondria of H/R injured H9c2 cells and subsequently increased the viability of H/R injured H9c2 cell through inhibiting the opening of mPTP and production of reactive oxygen species. In vivo results showed that CsA@PLGA-PEG-SS31 accumulated in ischemic myocardium of MI/RI rat heart. Apoptosis of cardiomyocyte was alleviated in MI/RI rats treated with CsA@PLGA-PEG-SS31, which resulted in the myocardial salvage and improvement of cardiac function. Besides, CsA@PLGA-PEG-SS31 protected myocardium from damage by reducing the recruitment of inflammatory cells and maintaining the integrity of mitochondrial function in MI/RI rats. CONCLUSION:CsA@PLGA-PEG-SS31 exhibited significant cardioprotective effects against MI/RI in rats hearts through protecting mitochondrial integrity, decreasing apoptosis of cardiomyocytes and myocardial infract area. Thus, CsA@PLGA-PEG-SS31 offered a promising therapeutic method for patients with acute myocardial infarction.

SUBMITTER: Zhang CX 

PROVIDER: S-EPMC6346555 | biostudies-other | 2019 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats.

Zhang Chang-Xiong CX   Cheng Ying Y   Liu Dao-Zhou DZ   Liu Miao M   Cui Han H   Zhang Bang-le BL   Mei Qi-Bing QB   Zhou Si-Yuan SY  

Journal of nanobiotechnology 20190125 1


<h4>Background</h4>Cyclosporin A (CsA) is a promising therapeutic drug for myocardial ischemia reperfusion injury (MI/RI) because of its definite inhibition to the opening of mitochondrial permeability transition pore (mPTP). However, the application of cyclosporin A to treat MI/RI is limited due to its immunosuppressive effect to other normal organ and tissues. SS31 represents a novel mitochondria-targeted peptide which can guide drug to accumulate into mitochondria. In this paper, mitochondria  ...[more]

Similar Datasets

| S-EPMC6609885 | biostudies-literature
| S-EPMC3730367 | biostudies-literature
| S-EPMC10676666 | biostudies-literature
| S-EPMC9458087 | biostudies-literature
| S-EPMC5618779 | biostudies-literature
2024-01-01 | GSE225105 | GEO
| S-EPMC2696550 | biostudies-literature
| S-EPMC7051900 | biostudies-literature
| S-EPMC3631228 | biostudies-literature
| S-EPMC10441752 | biostudies-literature